| David M Stettler, DO | |
|
4401 Harrison Blvd, Ogden, UT 84403-3195 | |
| (801) 993-9582 | |
| Not Available |
| Full Name | David M Stettler |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 22 Years |
| Location | 4401 Harrison Blvd, Ogden, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942246566 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | DO218658 (Oregon) | Secondary |
| 207L00000X | Anesthesiology | 6049595-1204 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mckay Dee Hospital | Ogden, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mountain West Anesthesia Llc | 9032018502 | 248 |
| Billings Clinic | 6002993516 | 659 |
News Archive
The vaping industry is filled with unknowns. Those unknowns are leading to more questions as the number of users dealing with injuries, or in some cases, death, continues to rise.
In the canton of Bern, only 14% of the adult population were infected with the coronavirus and developed antibodies against SARS-CoV-2.
Researchers in the University of Georgia's Center for Tropical and Emerging Global Diseases have found that a more intensive, less frequent drug regimen with currently available therapeutics could cure the infection that causes Chagas disease, a potentially life-threatening illness affecting up to 300,000 people in the United States.
Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.
› Verified 7 days ago
| Entity Name | Mountain West Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558391763 PECOS PAC ID: 9032018502 Enrollment ID: O20040103000057 |
News Archive
The vaping industry is filled with unknowns. Those unknowns are leading to more questions as the number of users dealing with injuries, or in some cases, death, continues to rise.
In the canton of Bern, only 14% of the adult population were infected with the coronavirus and developed antibodies against SARS-CoV-2.
Researchers in the University of Georgia's Center for Tropical and Emerging Global Diseases have found that a more intensive, less frequent drug regimen with currently available therapeutics could cure the infection that causes Chagas disease, a potentially life-threatening illness affecting up to 300,000 people in the United States.
Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David M Stettler, DO 1743 E 1150 N, Layton, UT 84040-7712 Ph: () - | David M Stettler, DO 4401 Harrison Blvd, Ogden, UT 84403-3195 Ph: (801) 993-9582 |
News Archive
The vaping industry is filled with unknowns. Those unknowns are leading to more questions as the number of users dealing with injuries, or in some cases, death, continues to rise.
In the canton of Bern, only 14% of the adult population were infected with the coronavirus and developed antibodies against SARS-CoV-2.
Researchers in the University of Georgia's Center for Tropical and Emerging Global Diseases have found that a more intensive, less frequent drug regimen with currently available therapeutics could cure the infection that causes Chagas disease, a potentially life-threatening illness affecting up to 300,000 people in the United States.
Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.
› Verified 7 days ago
Mark S Naisbitt, M.D., PC Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 4401 Harrison Boulevard, Mckay Dee Hospital, Ogden, UT 84403 Phone: 801-507-5248 Fax: 801-733-5618 | |
Dr. John L Haws, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Boulevard, Mckay Dee Hospital, Ogden, UT 84403 Phone: 801-507-5248 | |
Bryce Larre Egbert, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Blvd, Ogden, UT 84403 Phone: 801-387-2800 Fax: 770-701-6675 | |
Dr. Andrew W. Allen, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Blvd, Ogden, UT 84403 Phone: 801-727-2056 Fax: 770-701-6675 | |
Michael Laurence Smith, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Boulevard, Mckay Dee Hospital, Ogden, UT 84403 Phone: 801-507-5248 | |
Mr. Spencer B Hyde, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Blvd, Ogden, UT 84403 Phone: 801-387-2800 Fax: 770-701-6675 | |
Brian K Smith, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Boulevard, Mckay Dee Hospital, Ogden, UT 84403 Phone: 801-507-5248 Fax: 801-733-5618 |